Ceballos SA, Gaitán CLA, Ceballos GL

Idioma: Español
Referencias bibliográficas: 24
Paginas: 123-129
Archivo PDF: 192.35 Kb.

RESUMEN

Objetivos: Establecer si el tiempo bajo terapia antirretroviral altamente activa (TAAA), incluyendo inhibidores de proteasas del VIH-1, influye en la prevalencia de lesiones orales asociadas a infección por VIH (LO-VIH). Material y métodos: Cuatrocientos doce pacientes VIH+/SIDA sometidos a TAAA (pacientes bajo TAAA entre 24 y 28 semanas; y pacientes bajo TAAA ≥ 104 semanas), 304 varones, 108 mujeres; provenientes del Hospital Regional de Málaga “Carlos Haya”, fueron oralmente examinados y estableciéndose la prevalencia de lesiones orales asociadas a infección por VIH. Se consideró como inmunosupresión profunda a conteos de linfocitos CD4 + ‹ 200/mL y/o cargas virales › 10,000 copias/‹L. Se compararon las prevalencias de ambos grupos con las pruebas Chi cuadrado y exacta de Fisher. Se estableció Odds ratio para LO-VIH. Resultados: Las prevalencias más altas de LO-VIH, candidosis oral, leucoplasia vellosa, se encontraron en el grupo bajo 104 semanas de TAAA y en los pacientes con cargas virales altas. Conclusiones: El tiempo de terapia antirretroviral altamente activa no influye en la prevalencia de lesiones orales, ni en la probabilidad de padecer o no, lesiones orales asociadas a infección por VIH.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Scully C, Laskaris G, Pindborg J, Porter SR, Reichert P. Oral manifestations of HIV infection and their management. I. More common lesions. Oral Surg Oral Med Oral Pathol 1991; 71: 158-66.

2. Glick M, Muzyka BC, Lurie D, Salkin L. Oral manifestations associated with HIV-related disease as markers for immune suppression and AIDS. Oral Surg Oral Med Oral Pathol 1994; 77: 344-349.

3. Patton LL, Mckaig R, Strauss R, Rogers D, Eron JJ. Changing prevalence of oral manifestations of human immunodeficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol 2000; 89: 299-304.

4. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis of HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-1170.

5. Margiotta V, Campisi G, Mancuso S, Accurso V, Abadessa V. HIV infection: oral lesions, CD4+ cell count and viral load in an Italian study population. J Oral Pathol Med 1999; 28: 173-7.

6. Mallolas J, Arrizabalaga J, Loncha M, Gatell JM, Adán A, Martínez-Chamorro E et al. Cytomegalovirus disease in HIV-1-infected patients treated with protease inhibitors. AIODS 1997; 11(14): 1784-1786.

7. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Furher J, Satten GA et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Medicine 1998; 338(13): 853-860.

8. Pezzotti P, Napoli PA, Acciai S, Boros S, Urciuoli, Lazzeri V et al. Increasing survival time after AIDS in Italy: the role of new combination antirretroviral therapies. AIDS 1999; 13: 249-255.

9. Currier JS. Opportunistic infections in the age of highly active antiretroviral therapy. AIDS Patient Care and STDs 1998; 12(7): 521-524.

10. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 Protease inhibitors. A review for clinicians. JAMA 1997; 277(2): 145-153.

11. Cauda R, Tacconelli E, Tumbarello M, Morace G, De Bernardis F, Torosantucci A et al. Role of portease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. JAIDS 1999; 21: 20-25.

12. Diz Dios P, Ocampo A, Miralles C, Otero I, Iglesias I, Rayo N. Frequency of oropharyngeal candidiasis in HIV-infected patients on portease inhibitor therapy. Oral Surg Oral Med Oral Pathol 1999; 87(4): 437-441.

13. EC-Clearinghouse on oral problems related to HIV infection and WHO collaborating centre on oral manifestations of the immunodeficiency virus: Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med 1993; 22: 289-91.

14. Holmstrup P, Axel T. Classification and clinical manifestation of oral yeasts infections. Acta Odont Scand 1990; 48: 57-61.

15. Ceballos A, Gaitán L, Ceballos L. Oral lesions in HIV+/AIDS patients under highly active antiretroviral virus. AIDS Patient Care and STDs. In press.

16. Hoegl L, Thoma-Greber E, Rocken M, Korting HC. Shift from persistent oral pseudomembranous to erythematous candidosis in a human immunodeficiency virus (HIV)-infected patient upon combination treatment with an HIV protease inhibitor. Mycoses 1998; 41(5-6): 213-7.

17. Ceballos A, Aguirre JM, Bagán JV. Oral manifestation associated with human immunodeficiency virus infection in a Spanish population. J Oral Pathol Med 1996; 25: 523-6.

18. Laskaris G, Hadjivassiliou M, Stratigos J. Oral signs and symptoms in 160 Greek HIV infected patients. J Oral Pathol Med 1992; 21: 120-31.

19. Revankar SG, Sanche SE, Dib, Caceres M, Patterson. Effect of highly active antiretroviral therapy on recurrent oropharyngeal candidiasis in HIV-infected patients. AIDS 1998; 12(18): 2511-2513.

20. Chougnet C, Fowke KR, Mueller BU, Smith S, Zuckerman J, Jankelevitch S et al. Protease inhibitor and triple-drug therapy: cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment. AIDS 1998; 12: 2397-2406.

21. Ficarra G, Shillitoe EJ, Adler-Storthz K, Gaglioti D, Di Pietro M, Riccardi R. Oral melanotic macules in patients infected with human immunodeficiency virus. Oral Surg Oral Med Oral Pathol 1990; 70: 748-55.

22. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. “Bufalo hump” in men with HIV-1 infection. Lancet 1998; 351: 867-870.

23. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Fallon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351: 871-875.

24. Vlahov D, Graham N, Hoover D, Flynn C, Bartlett JG, Margolick JB et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users. JAMA 1998; 279(1): 35-40.